Herbert Irving Comprehensive Cancer Center
Investigator
Brian Henick, MD

212-305-5098

bh2682@cumc.columbia.edu
Dr. Henick is a medical oncologist specializing in thoracic malignancies and experimental therapeutics. He studied Economics and health care delivery as an undergraduate at the University of Pennsylvania, and attended Rutgers-New Jersey Medical School where he was inducted to the Gold Humanism Honor Society. He completed his post-graduate training in Internal Medicine and Hematology/Medical Oncology at Yale-New Haven Hospital, where he studied the role of the innate immune system as a predictor of sensitivity or resistance to immunotherapy. He has presented his research, supported by Conquer Cancer Foundation/ASCO awards, at national conferences including ASCO. Dr. Henick’s goal as a clinician and researcher is to improve upon existing treatment strategies, personalizing each patient’s care through computational study of cancer immunobiology and by being attuned to their values and needs alongside CUMC’s dedicated multidisciplinary team.
Condition |
Study Title |
Lung Cancer |
[ CLOSED ] Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
Cancer |
[ CLOSED ] Study of RO7198457 in locally advanced or metastatic tumors |
Cancer |
[ CLOSED ] Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers |
Solid Tumors |
Study of Drug Alone and In Combination with Nivolumab in Advanced Solid Tumors |
Solid Tumors |
[ CLOSED ] Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors |
Sarcoma |
[ CLOSED ] Study of HuMax-AXL-ADC in Patients with Sarcoma |
Cancer |
[ CLOSED ] Study of a Neoantigen Cancer Vaccine in Patients with Advanced Solid Tumors (Bladder, Colon, Stomach, Lung, Esophageal, or Rectal Cancer) |
Lung Cancer |
[ CLOSED ] GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer) |
Solid Tumors |
[ CLOSED ] A Study of ASP1951 in Subjects with Advanced Solid Tumors |
Lung Cancer |
[ CLOSED ] Radiation and Immune Checkpoints Blockade in Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Cancer |
Study of A Vaccine Targeting Shared Neoantigens in Subjects with Advanced Solid Tumors |
Cancer |
Study of ApricityOncology Smartphone Application Monitoring and Reporting Side Effects to their Nurses and Doctors |
Cancer |
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) |
Lung Cancer |
[ CLOSED ] Study of M7824 and cCRT in Patients with Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) |
Lung Cancer |
[ CLOSED ] Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors |
Lung Cancer |
[ CLOSED ] Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) |
Lung Cancer |
[ CLOSED ] Study of Telaglenastat in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) |
Cancer |
Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors |
Lung Cancer |
Tomivosertib With Anti-PD-(L)1 in Subjects With Non-Small Cell Lung Cancer (NSCLC) |
Cancer |
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer |
Autoimmune Disorders |
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer |
Cancer |
[ CLOSED ] Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer |
Lung Cancer |
Liver-Directed Radiotherapy Along with Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Liver Metastases |
Cancer |
Study of E-602 Alone or in Combination with Libtayo (Cemiplimab) in Patients with Advanced Cancer |
Cancer |
Study of BLU-222 Alone or in Combination with Other Cancer Therapy for Patients with Advanced Cancer |